stockrowPalisade Bio, Inc.
PALIPalisade Bio, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $250,000.00.
- Revenue
- +19,900.0%
- EPS
- +91.4%
- Free cash flow
- −318.4%
Quarter to June 2026, against a year earlier
Follow PALI
Alert me
Palisade Bio, Inc. (PALI) EV/Sales
As of 6 November 2026, Palisade Bio, Inc. (PALI) trades at a EV/Sales of 154×. Over the past ten years it has ranged from −873× (December 2022) to 20,647,674,913× (February 2015); the current reading is higher than 57% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2023 | −26.4× | — |
| FY2020 | 1,117× | — |
| FY2019 | −176× | — |
| FY2018 | 8.1× | (81.94%) |
| FY2017 | 44.9× | (96.76%) |
| FY2016 | 1,385× | (87.60%) |
| FY2015 | 11,173× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 420× | 5,019.68% |
| Mar 2023 | 8.2× | (99.27%) |
| Dec 2020 | 1,117× | — |
| Sep 2020 | −207× | — |
| 22 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ELDN Eledon Pharmaceuticals, Inc. compare | n/m |
| DRUG Bright Minds Biosciences Inc. compare | n/m |
| ARTV Artiva Biotherapeutics, Inc. compare | n/m |
| PLX Protalix BioTherapeutics, Inc. compare | 2.2× |
| RNAC Cartesian Therapeutics, Inc. compare | 78.2× |
| SLGL Sol-Gel Technologies Ltd. compare | 122× |
| PALI Palisade Bio, Inc. | 154× |
| IKT Inhibikase Therapeutics, Inc. compare | 395× |
| IFRX InflaRx N.V. compare | 1,845× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)